
zzso are active zzso agents that warrant combinations in clinical zzso This phase I combination study explored zzso administered as a zzso infusion followed by a 90-minute infusion zzso on days 1 and 14 of every zzso zzso zzso patients received doses of zzso and zzso ranging from zzso zzso and zzso zzso every 2 weeks for a total of 173 cycles, zzso zzso limiting zzso reported at doses 25 zzso zzso and 180 zzso zzso consisted of acute grade 3 zzso and zzso eventually associated with zzso and zzso and/or delayed grade 3 peripheral zzso zzso the recommended doses were 20 zzso zzso and 180 zzso zzso At this dose level, acute side effects were zzso zzso zzso zzso zzso and zzso Delayed zzso was mostly restricted to zzso grade zzso zzso data suggested no zzso zzso Five objective responses were observed in four patients with lung cancer and one unknown primary zzso zzso zzso In conclusion, toxicity including peripheral zzso was manageable at the recommended doses of 20 zzso zzso combined with 180 zzso zzso on days 1 and 14 every 28 zzso Promising zzso activity was observed in patients with zzso lung zzso 

